Venus Remedies (BOM:526953) E10: ₹34.23 (As of Mar. 2026)


BOM:526953 Venus Remedies Ltd BOM:526953
53 GF Score
Price ₹1,868.20
GF Value ₹467.09
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Venus Remedies E10?

Venus Remedies BOM:526953 -5.00% 53 E10 is ₹34.23 as of Mar. 2026. GuruFocus rates BOM:526953 with a GF Score™ of 53/100 and a GF Value™ of ₹467.09 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Venus Remedies's adjusted earnings per share data for the three months ended in Mar. 2026 was ₹35.530. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹34.23 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Venus Remedies's average E10 Growth Rate was 13.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-30), Venus Remedies's current stock price is ₹1868.20. Venus Remedies's E10 for the quarter that ended in Mar. 2026 was ₹34.23. Venus Remedies's Shiller PE Ratio of today is 54.58.

During the past 13 years, the highest Shiller PE Ratio of Venus Remedies was 56.85. The lowest was 9.93. And the median was 14.33.


Venus Remedies  (BOM:526953) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Venus Remedies's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=1868.20/34.23
=54.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Venus Remedies was 56.85. The lowest was 9.93. And the median was 14.33.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Venus Remedies E10 Related Terms


Venus Remedies E10 Historical Data

* Premium members only.

The historical data trend for Venus Remedies's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Venus Remedies E10 Chart

Venus Remedies Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 30.20 34.23

Venus Remedies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.20 30.56 31.91 33.37 34.23

BOM:526953 vs ZTS, UTHR: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Venus Remedies's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Venus Remedies Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Venus Remedies's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Venus Remedies's Shiller PE Ratio falls into.


BOM:526953
53GF Score
Venus Remedies Ltd BOM:526953
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Venus Remedies E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Venus Remedies's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=35.53/164.2724*164.2724
=35.530

Current CPI (Mar. 2026) = 164.2724.

Venus Remedies Quarterly Data

per share eps CPI Adj_EPS
201209 15.490 82.244 30.939
201212 16.480 83.774 32.316
201303 11.494 85.687 22.035
201403 0.000 91.425 0.000
201503 0.000 97.163 0.000
201603 0.000 102.518 0.000
201703 0.000 105.196 0.000
201803 0.000 109.786 0.000
201806 -4.700 111.317 -6.936
201809 0.340 115.142 0.485
201812 -9.500 115.142 -13.554
201903 -9.290 118.202 -12.911
201906 -3.300 120.880 -4.485
201909 0.340 123.175 0.453
201912 -0.780 126.235 -1.015
202003 -4.360 124.705 -5.743
202006 1.600 127.000 2.070
202009 10.550 130.118 13.319
202012 9.440 130.889 11.848
202103 28.440 131.771 35.455
202106 8.860 134.084 10.855
202109 17.320 135.847 20.944
202112 4.220 138.161 5.018
202203 0.180 138.822 0.213
202206 5.160 142.347 5.955
202209 3.990 144.661 4.531
202212 2.460 145.763 2.772
202303 8.280 146.865 9.261
202306 0.880 150.280 0.962
202309 7.440 151.492 8.068
202312 5.130 152.924 5.511
202403 7.870 153.035 8.448
202406 0.920 155.789 0.970
202409 2.630 157.882 2.736
202412 14.660 158.323 15.211
202503 15.710 157.552 16.380
202506 7.180 159.755 7.383
202509 15.060 162.289 15.244
202512 19.140 163.281 19.256
202603 35.530 164.272 35.530

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ₹34.23 mean?
Venus Remedies (BOM:526953) has a E10 of ₹34.23 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Venus Remedies and its competitors.
Is Venus Remedies' E10 too high?
Venus Remedies' current E10 is ₹34.23. Overall, Venus Remedies has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Venus Remedies' E10 compare to ZTS and UTHR?
Venus Remedies' E10 of ₹34.23 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Venus Remedies and its competitors. Venus Remedies's current E10 is ₹34.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Remedies stock overvalued right now?
Based on GuruFocus' analysis, Venus Remedies (BOM:526953) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹467.09, compared to a current price of ₹1,868.20 — trading 300% above its estimated fair value. The current E10 is ₹34.23. Venus Remedies' overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Venus Remedies (BOM:526953), the current E10 is ₹34.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Venus Remedies (BOM:526953) Overvalued in 2026?

Based on GuruFocus' analysis, Venus Remedies stock appears to be overvalued. The current stock price of ₹1,868.20 is trading 300% above its estimated GF Value™ of ₹467.09. GuruFocus considers Venus Remedies to be Significantly Overvalued.

Key valuation signals for BOM:526953:

  • E10: ₹34.23
  • GF Value™: ₹467.09 vs. price of ₹1,868.20 (300% above fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the BOM:526953 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Venus Remedies Business Description

Other Exchanges VENUSREM:India
Address Plot 51-52, Industrial Area, Phase 1, Panchkula, HR, IND, 134113
Venus Remedies Ltd is an Indian drug manufacturer. It is engaged in manufacturing and trading pharmaceutical products. The company produces biologically active food supplements which include food supplements are natural complexes containing minerals, vitamins, dietary fibers, extracts of medicinal herbs, amino acids and others.
53GF Score

Get the complete analysis for BOM:526953

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,868.20
Price
₹467.09
GF Value